NaviFUS Corp (6872) Fair Value & Analysis
Healthcare · TW · Market cap 1.2B TWD
Fair value as of: Jun 24, 2026
Analysis
NaviFUS Corp (6872) currently trades at 17.15 TWD, while our model-based Fair Value estimate is 23.56 TWD — implying the stock looks roughly 37.4% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan. The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others. It also develops NAVIRFA, a navigation system that uses optical 3D surgical tracking technology to monitor the 3D position of the needle tip during ultrasonic interventional procedures. The company was founded in 2015 and is based in Taipei, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is NaviFUS Corp (6872) undervalued?
What is the fair value of 6872?
What is the quality score of 6872?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.